<i>Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia</i>
Gail J. Roboz(Cornell University), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Román Galetto(Txcell (France)), Carrie Brownstein(Regeneron (United States)), Marina Konopleva(Albert Einstein College of Medicine), David A. Sallman(Moffitt Cancer Center), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Kate Backhouse(Cellectis (United States)), Nelli Bejanyan(Moffitt Cancer Center), Andrew J. Garton(Cellectis (United States)), Pinkal Desai(NewYork–Presbyterian Hospital), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Francisco J. Esteva(Northwell Health), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Hany Elmariah(Moffitt Cancer Center)
Cited by 11
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k